Cargando…

P398 COVID-19-associated pulmonary aspergillosis: Species distribution and susceptibility profiles

POSTER SESSION 3, SEPTEMBER 23, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: This study aimed to investigate the species distribution and susceptibility profiles of Aspergillus species isolated from patients admitted to the intensive care unit with severe COVID-19 in Isfahan, Iran, between April 2021 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Fakhim, Hamed, vaezi, Afsane, nasri, Elahe, Sadeghi, Somayeh, Shelerangkon, Mahsa, Rizi, Mahnaz Hosseini, Ghafel, Safiyeh, Badali, Hamid, Mirhendi, Hossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509778/
http://dx.doi.org/10.1093/mmy/myac072.P398
_version_ 1784797303085727744
author Fakhim, Hamed
vaezi, Afsane
nasri, Elahe
Sadeghi, Somayeh
Shelerangkon, Mahsa
Rizi, Mahnaz Hosseini
Ghafel, Safiyeh
Badali, Hamid
Mirhendi, Hossein
author_facet Fakhim, Hamed
vaezi, Afsane
nasri, Elahe
Sadeghi, Somayeh
Shelerangkon, Mahsa
Rizi, Mahnaz Hosseini
Ghafel, Safiyeh
Badali, Hamid
Mirhendi, Hossein
author_sort Fakhim, Hamed
collection PubMed
description POSTER SESSION 3, SEPTEMBER 23, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: This study aimed to investigate the species distribution and susceptibility profiles of Aspergillus species isolated from patients admitted to the intensive care unit with severe COVID-19 in Isfahan, Iran, between April 2021 and March 2022. METHODS: This retrospective study included intubated patients with COVID-19 in three referral COVID-19 hospitals. Tracheal aspirate (TA) samples were taken from 267 patients to investigate pulmonary co-infections. COVID-19-associated aspergillosis (CAPA) was defined according to the 2020 European Confederation of Medical Mycology/International Society of Human and Animal Mycosis consensus criteria. Aspergillus species obtained from samples were characterized based on conventional and molecular assays. In vitro antifungal susceptibility testing was performed on the obtained isolates according to the guidelines from the Clinical and Laboratory Standards Institute. RESULTS: The mean age of the patients was 61.73 ± 12.69 years. The mean length of hospitalization and admission in ICU were 18.77 ± 12.94 and 13.51 ± 9.83 days, respectively. A total of 61 (22.9%) patients presented with a single cavity lesion. Pulmonary artery pseudoaneurysm was seen in seven patients and post-COVID-19 changes were seen in all patients. Based on the conventional and molecular techniques, 72 isolates of Aspergillus species (26.9%), including A. flavus (10.1%%), A. fumigatus (8.6%%), A. niger (3.3%), A. tubingensis (2.9%), A. terreus (1.1%), A. luchuensis (0.37%) A. quadrillineatus, and (0.37%), were obtained from 267 patients. MIC results showed that all Aspergillus species were susceptible to all tested antifungal drugs. CONCLUSION: Access to priority clinical groups, improving the care of patients with simultaneous pulmonary aspergillosis with COVID-19, and identifying Aspergillus species are essential steps in the care cascade to manage those affected by them.
format Online
Article
Text
id pubmed-9509778
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95097782022-09-26 P398 COVID-19-associated pulmonary aspergillosis: Species distribution and susceptibility profiles Fakhim, Hamed vaezi, Afsane nasri, Elahe Sadeghi, Somayeh Shelerangkon, Mahsa Rizi, Mahnaz Hosseini Ghafel, Safiyeh Badali, Hamid Mirhendi, Hossein Med Mycol Oral Presentations POSTER SESSION 3, SEPTEMBER 23, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: This study aimed to investigate the species distribution and susceptibility profiles of Aspergillus species isolated from patients admitted to the intensive care unit with severe COVID-19 in Isfahan, Iran, between April 2021 and March 2022. METHODS: This retrospective study included intubated patients with COVID-19 in three referral COVID-19 hospitals. Tracheal aspirate (TA) samples were taken from 267 patients to investigate pulmonary co-infections. COVID-19-associated aspergillosis (CAPA) was defined according to the 2020 European Confederation of Medical Mycology/International Society of Human and Animal Mycosis consensus criteria. Aspergillus species obtained from samples were characterized based on conventional and molecular assays. In vitro antifungal susceptibility testing was performed on the obtained isolates according to the guidelines from the Clinical and Laboratory Standards Institute. RESULTS: The mean age of the patients was 61.73 ± 12.69 years. The mean length of hospitalization and admission in ICU were 18.77 ± 12.94 and 13.51 ± 9.83 days, respectively. A total of 61 (22.9%) patients presented with a single cavity lesion. Pulmonary artery pseudoaneurysm was seen in seven patients and post-COVID-19 changes were seen in all patients. Based on the conventional and molecular techniques, 72 isolates of Aspergillus species (26.9%), including A. flavus (10.1%%), A. fumigatus (8.6%%), A. niger (3.3%), A. tubingensis (2.9%), A. terreus (1.1%), A. luchuensis (0.37%) A. quadrillineatus, and (0.37%), were obtained from 267 patients. MIC results showed that all Aspergillus species were susceptible to all tested antifungal drugs. CONCLUSION: Access to priority clinical groups, improving the care of patients with simultaneous pulmonary aspergillosis with COVID-19, and identifying Aspergillus species are essential steps in the care cascade to manage those affected by them. Oxford University Press 2022-09-20 /pmc/articles/PMC9509778/ http://dx.doi.org/10.1093/mmy/myac072.P398 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Oral Presentations
Fakhim, Hamed
vaezi, Afsane
nasri, Elahe
Sadeghi, Somayeh
Shelerangkon, Mahsa
Rizi, Mahnaz Hosseini
Ghafel, Safiyeh
Badali, Hamid
Mirhendi, Hossein
P398 COVID-19-associated pulmonary aspergillosis: Species distribution and susceptibility profiles
title P398 COVID-19-associated pulmonary aspergillosis: Species distribution and susceptibility profiles
title_full P398 COVID-19-associated pulmonary aspergillosis: Species distribution and susceptibility profiles
title_fullStr P398 COVID-19-associated pulmonary aspergillosis: Species distribution and susceptibility profiles
title_full_unstemmed P398 COVID-19-associated pulmonary aspergillosis: Species distribution and susceptibility profiles
title_short P398 COVID-19-associated pulmonary aspergillosis: Species distribution and susceptibility profiles
title_sort p398 covid-19-associated pulmonary aspergillosis: species distribution and susceptibility profiles
topic Oral Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509778/
http://dx.doi.org/10.1093/mmy/myac072.P398
work_keys_str_mv AT fakhimhamed p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles
AT vaeziafsane p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles
AT nasrielahe p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles
AT sadeghisomayeh p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles
AT shelerangkonmahsa p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles
AT rizimahnazhosseini p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles
AT ghafelsafiyeh p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles
AT badalihamid p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles
AT mirhendihossein p398covid19associatedpulmonaryaspergillosisspeciesdistributionandsusceptibilityprofiles